Medication adherence in patients with dementia: An Austrian cohort study

Alzheimer Disease and Associated Disorders

Volumn 28, Issue 2, 2014, Pages 128-133

  Haider, Bernhard ^a   Schmidt, Reinhold ^e   Schweiger, Christine ^b   Forstner, Thomas ^c   Labek, Anna ^a   Lampl, Christian ^d  

^a Department of Neurology LNK Wagner Jauregg ^*  (Austria)

^b Department of Ophthalmology   (Austria)

^c JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

^d Hospital of the Sisters of Charity   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Adherence; Alzheimer disease; Dementia; Medication Possession Ratio; Nonpersistence

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGED; ARTICLE; AUSTRIA; COHORT ANALYSIS; DEMENTIA; FEMALE; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEDICATION POSSESSION RATIO; PATIENT COMPLIANCE; PRIORITY JOURNAL; STATISTICAL PARAMETERS; TREATMENT DURATION; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUSTRIA; CHOLINESTERASE INHIBITORS; COHORT STUDIES; DEMENTIA; DOPAMINE AGENTS; FEMALE; GALANTAMINE; HUMANS; INDANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MEMANTINE; PHENYLCARBAMATES; PIPERIDINES; RETROSPECTIVE STUDIES;

EID: 84901610973     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000006     Document Type: Article

References (31)

1. Doody RS, Geldmacher DS, Gordon B, et al. Donepezil study group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donezepil in patients with Alzheimer disease. Arch Neurol. 2001;58:427-433. (Pubitemid 32217459)
2. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer's disease: A systemic review and meta- analysis. Clin Intervent Aging. 2008;3:211-225. (Pubitemid 352037861)
3. Cummings JL. Use of cholinesterase inhibitors in clinical practice, evidence-based recommendations. Am J Geriatr Psychiatry. 2003;11:131-145. (Pubitemid 36254187)
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2008;25:CD005593.
5. McShane R, Areosa SA, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;16:CD003154.
6. Wimo A, Winblad B, Stöffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics. 2003;21:327-340. (Pubitemid 36403437)
7. Pariente A, Fourrier-Reglat A, Bazin F, et al. Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology. 2012;78:957-963.
8. Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1:5-7.
9. Abugosh S, Kogut S. Comparison of persistence rates of acetylcholine- esterase inhibitors in a state Medicaid program. Patient Prefer Adherence. 2008;2:79-85.
10. Amuah JE, Hogan DB, Eliasziw M, et al. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2010;19:670-679.
11. Singh G, Thomas SK, Arcona SK, et al. Treatment persistency with rivastigmine and donepezil in a large state Medicaid program. J Am Geriatr Soc. 2005;53:1269-1270. (Pubitemid 41632540)
12. Suh DC, Thomas SK, Valiyeva E, et al. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging. 2005;22:695-707. (Pubitemid 41138981)
13. Sicras-Mainar A, Vergera J, Leon-Colombo T, et al. Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine. Rev Neurol. 2006;43:449-453. (Pubitemid 47574007)
14. Kröger E, van Marum R, Souverein P, et al. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study. Drugs Aging. 2010;27:663-675.
15. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497. (Pubitemid 41127293)
16. Barat I, Andreasen F, Damsgaard EM. Drug therapy in the elderly: what doctors believe and patients actually do. Br J Clin Pharmacol. 2001;51:615-622. (Pubitemid 32862751)
17. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva, Switzerland: World Health Organization; 1993: 36-40.
18. Blanford L, Dans PE, Ober JD, et al. Analyzing variations in medication compliance related to individual drug, drug class and prescribing physician. J Manag Care Pharm. 1999;5:47-51.
19. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-574. (Pubitemid 44336271)
20. Mabotuwana T, Warren J, Gaikwad R, et al. Analysis of medication possession ratio for improved blood pressure control- towards a semantic web technology enabled workbench. Health Care and Inform Rev Online. 2008;12:19-24.
21. Mucha L, Shaohung S, Cuffel B, et al. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J Manag Care Pharm. 2008;14:451-461.
22. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-397. (Pubitemid 351665469)
23. Starner C, Gleason P. Cholinesterase inhibitor utilization patterns: just because it can be counted does not mean it counts. J Manag Care Pharm. 2008;14:462-464.
24. Dybicz SB, Keohane DJ, Erwin WG, et al. Patterns of cholinesterase inhibitor use in the nursing home setting: A retrospective analysis. Am J Geriatr Pharmacother. 2006;4: 154-160. (Pubitemid 44057811)
25. Herrmann N, Binder C, Dalziel W, et al. Persistence with cholinesterase inhibitor therapy for dementia: An observational administrative health database study. Drugs Aging. 2009;26:403-407.
26. Crystal S, Akincigil A, Bilder S, et al. Studying prescription drug use and outcomes with Medicaid claims data: strengths, limitations, and strategies. Med Care. 2007;45:58-65.
27. Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol. 2004;11:274-285.
28. DiMatteo MR, Haskard Zolnierek KB. Physician communication and patient adherence to treatment: A meta-analysis. Med Care. 2009;47:826-834.
29. Sabate E. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization; 2003.
30. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest. 2006;130:65-72.
31. Arlt S, Lindner R, Rösler A, et al. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25:1033-1047.